US EditionEli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
Lilly lifted its 2026 profit outlook after first-quarter sales beat estimates, with Zepbound and Mounjaro demand offsetting early rollout questions for Foundayo.
- On Thursday, Eli Lilly reported first-quarter earnings of $7.4 billion and revenue of $19.8 billion, exceeding Wall Street expectations. Adjusted profit reached $8.26 per share, surpassing the $7.06 estimate from Zacks Investment Research.
- Steady demand for weight-loss and diabetes drugs Zepbound and Mounjaro fueled the performance. These results mark Lilly's first financial report since launching its once-daily oral GLP-1 pill, Foundayo, earlier this month.
- Foundayo prescriptions reached 3,707 in the week ended April 17, falling short of analysts' expectations of around 8,000. Investors are monitoring the rollout as a key test of whether Lilly can gain market share from rival Novo.
- CEO David Ricks stated, "Foundayo will meaningfully expand the number of people who can benefit from GLP-1s," emphasizing the drug's market potential. The company continues navigating lower prices and government deals while managing drug demand.
- Lilly raised its full-year earnings outlook to $35.50 to $37 per share, with projected revenue between $82 billion and $85 billion. This compares to the prior view of $33.50 to $35 per share, reflecting confidence in sustained drug demand.
28 Articles
28 Articles
Eli Lilly Sales Surge 56% as Booming GLP-1 Demand Eclipses Lower Prices
Eli Lilly isn’t just a pharmaceutical giant anymore; it’s a global appetite suppressant for an economy built on over-consumption. The company blew past Wall Street’s first-quarter expectations, with revenue surging 56% to $19.8 billion, well above the $17.8 billion analysts projected. The results were driven by a 65% jump in volume amid booming demand for weight-loss drugs like Lilly’s Mounjaro and Zepbound and rival Novo Nordisk’s Wegovy. Tha…
Novo's American competitor Eli Lilly has just published figures for the first quarter of the year. The company reports better revenue growth than expected. The company's revenue in the quarter was $19.8 billion...
Times of India
The Economic TimesUS Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growth
Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for its weight-loss and diabetes drugs Zepbound and Mounjaro, in its first results since launching oral GLP-1 pill Foundayo.
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
